Cholesterol Reconsidered:
What Your Body Is
Actually Telling You

The Prescription That Doesn't Ask Why

You go in for a routine physical. Your labs come back. And somewhere in the conversation, you hear: "Your cholesterol is high. I'd like to start you on a statin."

For millions of people, that's where the conversation ends. The number is high, the medication exists, the prescription is written. What rarely gets asked — what terrain medicine always asks — is: why is it high?

Because cholesterol doesn't rise randomly. It rises in response to something. And understanding what that something is changes everything about how we approach cardiovascular support.

What Cholesterol Is Actually Doing

Cholesterol is not a toxin. It is one of the most essential molecules in human physiology. Every cell membrane in your body depends on it for stability and function. Your steroid hormones — cortisol, estrogen, progesterone, testosterone, DHEA — are all synthesized from cholesterol. Your brain, which contains roughly 25% of the body's total cholesterol, uses it for myelin production, membrane integrity, and neurological signaling. Your vitamin D pathway begins with it. And your liver requires it to produce bile — the compound you need to digest dietary fat and absorb fat-soluble vitamins A, D, E, and K.

Here's the piece that reframes everything: when blood vessel walls sustain injury — from chronic inflammation, from elevated blood sugar, from oxidative stress — your body sends cholesterol to the site as part of a repair cascade. It is a first responder, not an instigator.

Finding cholesterol in atherosclerotic plaque is like finding firefighters at the scene of a fire. They didn't cause it. They were called there. Suppressing cholesterol with a statin doesn't repair the underlying damage. It removes the repair crew while the fire continues to burn.

Why the "Normal" Threshold Keeps Moving

One of the least examined chapters in the cholesterol story is how dramatically the definition of "too high" has shifted over the past four decades. The 1988 guidelines identified 240 mg/dL as elevated, with dietary therapy as the first-line approach. By 2001, revised guidelines had expanded statin eligibility by 140% in a single update — not because the science of heart disease had fundamentally changed, but because the eligibility thresholds had. The LDL target of under 70 mg/dL introduced in 2004 was not derived from clinical trial evidence.

At multiple points along the way, the majority of panel members writing those guidelines had documented financial ties to statin manufacturers. These conflicts were reported in peer-reviewed journals and mainstream media — not as fringe allegations, but as a matter of public record. Understanding this history doesn't mean rejecting cardiology. It means asking better questions.

The Upstream Drivers That Actually Matter

Chronic systemic inflammation — measured by hsCRP, homocysteine, and fibrinogen — is the primary initiator of the atherosclerotic cascade. It damages the endothelial lining of blood vessels and creates the injured terrain that cholesterol is then sent to repair. Inflammation doesn't appear on a standard lipid panel.

Insulin resistance elevates triglycerides, lowers HDL, and shifts LDL toward the small, dense particle pattern that's genuinely atherogenic. Fasting insulin is more predictive of cardiovascular events than total LDL in multiple large studies. And here's a painful irony: the low-fat dietary guidelines introduced in the 1970s replaced fat with refined carbohydrates — dramatically accelerating the insulin resistance epidemic that actually drives cardiovascular disease.

Thyroid dysfunction is one of the most missed connections in conventional medicine. Thyroid hormone directly regulates the LDL receptors on liver cells. When thyroid function is reduced — even subclinically — LDL clearance slows and serum cholesterol rises. This is documented endocrinology. Patients routinely receive statin prescriptions without a full thyroid evaluation.

Chronic stress and HPA dysregulation drive cholesterol demand. Cortisol is synthesized from cholesterol. When the stress response is chronically activated, the body upregulates cholesterol production to meet demand. A statin prescribed to a chronically stressed person suppresses the signal without addressing the source.

Compromised bile metabolism is perhaps the most overlooked piece of all. The liver uses cholesterol to make bile acids. When bile flow is impaired — from age, from gallbladder removal, from liver stress — the liver compensates by producing more cholesterol to replace what's being lost rather than recycled. On a standard lipid panel, this looks like "high cholesterol." In terrain medicine, it's a bile insufficiency problem. Millions of people who've had their gallbladder removed were sent home without any metabolic support — and many are now on statins for a problem that has nothing to do with statin deficiency.

What the Statin Conversation Is Missing

Statins block the mevalonate pathway — which reduces cholesterol synthesis. But that same pathway also produces CoQ10, the essential cofactor your mitochondria need to generate energy. The organs with the highest CoQ10 demand are the heart, the liver, the kidneys, and skeletal muscle.

A medication prescribed to protect the heart depletes the mitochondrial energy substrate the heart muscle runs on. Statin-induced cardiomyopathy is documented in the peer-reviewed literature. The symptoms — fatigue, reduced exercise tolerance, shortness of breath — are frequently attributed to aging rather than the medication itself.

For women specifically, the evidence base for statin therapy is thinner than most people realize. The foundational clinical trials enrolled 75–85% men with established heart disease. Multiple analyses specifically examining women in primary prevention — no prior cardiac events — have found no statistically significant mortality benefit. The data was extrapolated from a completely different population.

This isn't a case against all statins. For men with established cardiovascular disease and high inflammatory burden, modest benefit has been demonstrated. But the terrain medicine question is unavoidable: for the millions of people prescribed statins for primary prevention — particularly women, older adults, and those with unaddressed thyroid dysfunction or bile insufficiency — what is the actual risk-benefit picture, and has the upstream terrain ever been properly investigated?

What Terrain-Based Cardiovascular Support Looks Like

When we identify and address the actual upstream drivers — the inflammation, the insulin resistance, the thyroid picture, the bile insufficiency, the chronic stress physiology — cholesterol frequently normalizes without pharmacological intervention. Not because we suppressed it, but because we resolved what it was responding to.

Terrain support for cardiovascular recovery includes CoQ10 to restore mitochondrial function, magnesium for endothelial health and vascular calcification prevention, omega-3 fatty acids for anti-inflammatory signaling, vitamin K2 to direct calcium to bone rather than vessel walls, methylated B vitamins to address homocysteine, and bile support for those with compromised fat metabolism. And always — always — investigating why the terrain became inflamed in the first place.

If any of this resonates — if you've been handed a statin prescription and something hasn't felt complete about that conversation — the Clarity Assessment is a free place to begin understanding your own terrain picture.